SKYCLARYS (omaveloxolone)

article

Rare disease spotlight: first EU-approved treatment for Friedreich’s ataxia

29 February 2024 | By Catherine Eckford (European Pharmaceutical Review)

In this exclusive article, Biogen’s Vice President and Head of the Neuromuscular Development Unit, Dr Toby Ferguson, discusses the current rare disease landscape and recent developments in treating Friedreich’s ataxia (FA).

news

Biogen to acquire rare disease drugmaker for $7.3b

31 July 2023 | By Catherine Eckford (European Pharmaceutical Review)

As part of its acquisition of Reata Pharmaceuticals, Biogen will add the first US Food and Drug Administration (FDA)-approved treatment for Friedreich’s ataxia to its portfolio.